Regulatory Disputes with HHS: When to Negotiate and When to Litigate | McDermott

Regulatory Disputes with HHS: When to Negotiate and When to Litigate

Overview



Access the takeaways here.

For healthcare and life sciences companies, regulatory disputes with the U.S. Department of Health and Human Services (HHS) and its operating divisions can present significant economic costs and reputational risks. Efficient resolutions of such disputes are always preferable and require an understanding of the law, the institutional relationships between the relevant HHS operating division and other parts of the Executive Branch and agency personnel. When a company cannot reach an efficient resolution through negotiation and litigation is the only option, the company must vindicate its rights in a principled way that mitigates reputation risks.

Arm in-house healthcare and life sciences lawyers with the knowledge they need to navigate regulatory disputes with HHS and its operating divisions. Learn from former senior government officials:

  • The basics of the governing legal framework, which is the Administrative Procedure Act
  • Best practices for dispute resolution through advocacy at the division level and department levels and through litigation
  • A Case Study: APA negotiation and litigation approaches with one key HHS operating division, the U.S. Food and Drug Administration (FDA)
  • Regulatory areas that may give rise to disputes in the Biden Administration

Registration Information

12:00 pm – 1:00 pm EST

Dig Deeper

Boston, MA / In-person / November 13, 2025

Life Sciences Investment Forum 2025

Chicago, IL & Virtual / In-person / October 28, 2025

Healthcare Litigation, Compliance, and Investigations Forum 2025

New York, NY / In-person / October 16, 2025

HPE NYC 2025

Atlanta, Georgia / Speaking Engagements / October 8, 2025

Advanced Health Law

Verona, WI / Speaking Engagements / September 24-25, 2025

Open@Epic Conference 2025